Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813218 | 0.94 | SMN1; SMN2 (0.53) | MAPK1RAB9ASMN1; SMN2CASP3TDP1 | |
| SCHEMBL9760236 | 0.92 | SMN1; SMN2 (0.51) | MAPK1RAB9ASMN1; SMN2CASP3TDP1 | |
| SCHEMBL6043712 | 0.90 | MAPT (0.64) | MAPK1RAB9ASMN1; SMN2CASP3TDP1 | |
| SCHEMBL20492122 | 0.87 | TDP1 (0.65) | RAB9ASMN1; SMN2TDP1L3MBTL1MAPT | |
| SCHEMBL29132345 | 0.87 | RAB9A (0.52) | MAPK1RAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL2743018 | 0.85 | HPGD (0.61) | MAPK1RAB9ASMN1; SMN2CASP3TDP1 | |
| SCHEMBL23043116 | 0.85 | MEN1 (0.45) | MAPK1RAB9ASMN1; SMN2CASP3MAPT | |
| SCHEMBL2567987 | 0.85 | TDP1 (0.61) | RAB9ASMN1; SMN2TDP1L3MBTL1MAPT | |
| SCHEMBL2565857 | 0.85 | TDP1 (0.61) | RAB9ASMN1; SMN2TDP1L3MBTL1MAPT | |
| SCHEMBL2567938 | 0.85 | TDP1 (0.61) | RAB9ASMN1; SMN2TDP1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188083-A1 | Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-12 | — | — | US | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2022272313-A1 | MODULATORS OF HISTONE ACETYLTRANSFERASE 1 AND METHODS OF TREATMENT THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| EP-2637503-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| WO-2012062157-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES THEREOF AS SELECTIVE GLYCOSIDASE INHIBITORS | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
| US-8067625-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8049022-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20100152081-A1 | Fluorosurfactants | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20090312432-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090264525-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-1996005187-A1 | (4-(3-AMINOMETHYLPHENYL)THIAZOL-2-YL)-GUANIDINES AS H2-RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | MAPK1 3131/4885RAB9A 2232/4885SMN1; SMN2 2251/4885 |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885RAB9A 405/4885SMN1; SMN2 362/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885RAB9A 405/4885SMN1; SMN2 362/4885 |
| US-20090312432-A1 | FLUOROSURFACTANTS | SGMS2, FASN, SGMS1 | MAPK1 4007/4885RAB9A 3703/4885SMN1; SMN2 2410/4885 |
| US-20100152081-A1 | Fluorosurfactants | CBR3, FPR3, NOX3 | MAPK1 3818/4885RAB9A 1614/4885SMN1; SMN2 3606/4885 |
| US-20090264525-A1 | FLUOROSURFACTANTS | FASN, FFAR3, SGMS2 | MAPK1 3912/4885RAB9A 3063/4885SMN1; SMN2 2379/4885 |
| US-20250188083-A1 | Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof | EP300, HDAC1, NAT1 | MAPK1 802/4885RAB9A 3130/4885SMN1; SMN2 2126/4885 |
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | MAPK1 1956/4885RAB9A 1091/4885SMN1; SMN2 4839/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | MAPK1 2772/4885RAB9A 405/4885SMN1; SMN2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.